Autolus Therapeutics (AUTL) Competitors $1.85 +0.01 (+0.54%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$1.88 +0.02 (+1.35%) As of 08/14/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AUTL vs. AMRX, NAMS, XENE, KNSA, RXRX, CNTA, ARWR, IDYA, BHC, and BLTEShould you be buying Autolus Therapeutics stock or one of its competitors? The main competitors of Autolus Therapeutics include AMNEAL PHARMACEUTICALS (AMRX), NewAmsterdam Pharma (NAMS), Xenon Pharmaceuticals (XENE), Kiniksa Pharmaceuticals International (KNSA), Recursion Pharmaceuticals (RXRX), Centessa Pharmaceuticals (CNTA), Arrowhead Pharmaceuticals (ARWR), IDEAYA Biosciences (IDYA), Bausch Health Cos (BHC), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry. Autolus Therapeutics vs. Its Competitors AMNEAL PHARMACEUTICALS NewAmsterdam Pharma Xenon Pharmaceuticals Kiniksa Pharmaceuticals International Recursion Pharmaceuticals Centessa Pharmaceuticals Arrowhead Pharmaceuticals IDEAYA Biosciences Bausch Health Cos Belite Bio AMNEAL PHARMACEUTICALS (NASDAQ:AMRX) and Autolus Therapeutics (NASDAQ:AUTL) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability. Do insiders and institutionals hold more shares of AMRX or AUTL? 31.8% of AMNEAL PHARMACEUTICALS shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 26.6% of AMNEAL PHARMACEUTICALS shares are held by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has stronger earnings and valuation, AMRX or AUTL? AMNEAL PHARMACEUTICALS has higher revenue and earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than AMNEAL PHARMACEUTICALS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAMNEAL PHARMACEUTICALS$2.79B1.05-$116.89M$0.01939.00Autolus Therapeutics$10.12M48.65-$220.66M-$0.84-2.20 Which has more risk and volatility, AMRX or AUTL? AMNEAL PHARMACEUTICALS has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. Is AMRX or AUTL more profitable? AMNEAL PHARMACEUTICALS has a net margin of 0.12% compared to Autolus Therapeutics' net margin of 0.00%. Autolus Therapeutics' return on equity of -56.18% beat AMNEAL PHARMACEUTICALS's return on equity.Company Net Margins Return on Equity Return on Assets AMNEAL PHARMACEUTICALS0.12% -189.49% 6.17% Autolus Therapeutics N/A -56.18%-29.61% Do analysts prefer AMRX or AUTL? AMNEAL PHARMACEUTICALS presently has a consensus target price of $11.60, suggesting a potential upside of 23.54%. Autolus Therapeutics has a consensus target price of $9.12, suggesting a potential upside of 392.97%. Given Autolus Therapeutics' higher probable upside, analysts plainly believe Autolus Therapeutics is more favorable than AMNEAL PHARMACEUTICALS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AMNEAL PHARMACEUTICALS 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor AMRX or AUTL? In the previous week, Autolus Therapeutics had 7 more articles in the media than AMNEAL PHARMACEUTICALS. MarketBeat recorded 18 mentions for Autolus Therapeutics and 11 mentions for AMNEAL PHARMACEUTICALS. Autolus Therapeutics' average media sentiment score of 0.77 beat AMNEAL PHARMACEUTICALS's score of 0.48 indicating that Autolus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AMNEAL PHARMACEUTICALS 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Autolus Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAMNEAL PHARMACEUTICALS and Autolus Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AUTL vs. The Competition Export to ExcelMetricAutolus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$489.70M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-2.2020.4930.2925.74Price / Sales48.65356.37463.41115.83Price / CashN/A43.0338.2159.48Price / Book1.428.608.826.15Net Income-$220.66M-$54.65M$3.25B$265.06M7 Day Performance-20.60%5.86%3.70%2.60%1 Month Performance-25.70%8.86%5.84%2.83%1 Year Performance-50.67%13.33%29.92%25.58% Autolus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AUTLAutolus Therapeutics3.0217 of 5 stars$1.85+0.5%$9.12+393.0%-48.5%$489.70M$10.12M-2.20330News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionAMRXAMNEAL PHARMACEUTICALS3.054 of 5 stars$7.96+1.7%$11.60+45.7%+20.2%$2.45B$2.79B13.278,100News CoverageInsider TradeNAMSNewAmsterdam Pharma3.5361 of 5 stars$21.66+1.8%$41.30+90.7%+48.1%$2.39B$45.56M0.004XENEXenon Pharmaceuticals2.0303 of 5 stars$33.16+8.7%$54.82+65.3%-1.9%$2.34B$9.43M0.00210Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumeKNSAKiniksa Pharmaceuticals International2.6464 of 5 stars$32.95+3.0%$41.17+24.9%+30.8%$2.33B$423.24M799.50220Positive NewsInsider TradeRXRXRecursion Pharmaceuticals1.4777 of 5 stars$5.80+2.1%$7.00+20.7%-10.2%$2.31B$58.84M0.00400Gap DownCNTACentessa Pharmaceuticals2.6345 of 5 stars$16.08-4.3%$28.10+74.8%+40.0%$2.25B$6.85M0.00200Earnings ReportAnalyst ForecastARWRArrowhead Pharmaceuticals4.1504 of 5 stars$16.47+3.4%$43.71+165.4%-17.3%$2.20B$3.55M-11.76400Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionIDYAIDEAYA Biosciences4.4495 of 5 stars$25.00+3.0%$48.09+92.4%-33.7%$2.13B$7M0.0080BHCBausch Health Cos4.1629 of 5 stars$5.78+1.1%$9.00+55.8%+35.8%$2.11B$9.63B1.5220,700News CoverageInsider TradeBLTEBelite Bio2.7327 of 5 stars$69.79+6.2%$96.67+38.5%+38.2%$2.09BN/A0.0010News CoverageEarnings ReportAnalyst Revision Related Companies and Tools Related Companies AMNEAL PHARMACEUTICALS Competitors NewAmsterdam Pharma Competitors Xenon Pharmaceuticals Competitors Kiniksa Pharmaceuticals International Competitors Recursion Pharmaceuticals Competitors Centessa Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors IDEAYA Biosciences Competitors Bausch Health Cos Competitors Belite Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AUTL) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.